Gyre Therapeutics Partners with Rhythm Biosciences to Enhance Cancer Diagnostics through Real-World Data

Strategic Collaboration to Advance Cancer Diagnostics: datma and Rhythm Biosciences Join Forces

In a significant development for the cancer diagnostics landscape, datma, a leader in federated real-world data access, partners with Rhythm Biosciences Ltd, known for its innovative geneType™ risk assessment portfolio. This collaboration, announced on December 22, 2025, seeks to utilize datma's advanced federated data platform, datma.FED, to enhance the commercialization of Rhythm's genomic-integrated cancer risk prediction tools. As the demand for precision medicine grows, the integration of high-quality, real-world data becomes crucial. This partnership aims to address the challenges posed by fragmented data sources and stringent privacy regulations, which often hinder the progress of research and development in this sector.

The datma.FED platform stands out by enabling secure access to de-identified data from multiple healthcare organizations without the need for centralization. This innovative approach not only protects patient privacy but also streamlines the process of data utilization for research initiatives. The collaboration will specifically explore how longitudinal, de-identified clinical data can improve Rhythm’s genomic-integrated risk scoring technologies. By leveraging these data insights, the partnership aims to generate robust clinical utility evidence and health economic models, which are essential for engaging with healthcare systems about the adoption of population-based risk stratification tools.

Both Noah Nasser, CEO of datma, and Dr. Erika Spaeth, Director of Clinical Affairs at Rhythm Biosciences, emphasize the importance of this collaboration in advancing cancer diagnostics. Nasser highlights the increasing demand for secure data access to support diagnostic and therapeutic research, while Spaeth points to high-quality data's role in showcasing the clinical relevance of genomic risk prediction tools. This partnership represents a pivotal opportunity to enhance Rhythm’s portfolio and to facilitate effective implementation strategies within healthcare systems, ultimately aiming to improve patient outcomes through more accurate cancer risk assessments.

In addition to the collaboration, the partnership underscores a broader trend in the healthcare industry toward leveraging real-world data for improving clinical decision-making. As genomic-integrated tools gain prominence, ensuring access to quality data remains a priority for companies like Rhythm Biosciences. The successful integration of datma's federated data approach could set a precedent for future collaborations in the field, paving the way for more innovative solutions in cancer diagnostics.

This alliance not only reflects the evolving landscape of cancer diagnostics but also reinforces the critical role that data accessibility plays in the development of advanced predictive tools. By combining their strengths, datma and Rhythm aim to make significant strides in the fight against cancer, demonstrating the potential of collaborative efforts in transforming healthcare outcomes.